(NASDAQ: CADL) Candel Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 26.43%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 40.98%.
Candel Therapeutics's earnings in 2025 is -$22,136,000.On average, 8 Wall Street analysts forecast CADL's earnings for 2025 to be -$19,663,424, with the lowest CADL earnings forecast at -$23,670,767, and the highest CADL earnings forecast at -$13,026,607. On average, 7 Wall Street analysts forecast CADL's earnings for 2026 to be -$50,190,589, with the lowest CADL earnings forecast at -$75,425,866, and the highest CADL earnings forecast at -$26,514,333.
In 2027, CADL is forecast to generate -$13,537,131 in earnings, with the lowest earnings forecast at -$41,423,842 and the highest earnings forecast at $36,889,507.